Drugs /

lansoprazole

Back to Drugs List

Overview

NCI Definition [1]:
A substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity. Lansoprazole prodrug is converted to an active sulfonamide derivative in the acidic environment of the gastric parietal cell; the sulfonamide derivative binds to the gastric proton pump H+/K+ ATPase and forms a stable disulfide bond with the sulfhydryl group near the potassium-binding site on the luminal side, resulting in inactivation of the ATPase and a reduction in gastric acid secretion. This agent does not have anticholinergic or histamine H2 -receptor antagonistic properties.

Clinical Trials

View Clinical Trials for lansoprazole

Lansoprazole has been investigated in 3 clinical trials, of which 2 are open and 1 is closed. Of the trials investigating lansoprazole, 3 are phase 2 (2 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for lansoprazole clinical trials.

Breast carcinoma, cervical carcinoma, and endometrial carcinoma are the most common diseases being investigated in lansoprazole clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Lansoprazole
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Lansoprazole
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating lansoprazole and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
tap brand of lansoprazole, 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole, lansoprazole (product), lansoprazole, prevacid, lansoprazole [chemical/ingredient], lansoprazole, lansoprazoles, lansoprazolum, ogastro, lansoprazole abbot brand, lansoprazole (substance), abbot brand of lansoprazole, lansoprazole tap brand, lansoprazol
NCIT ID [1]:
C29150
SNOMED ID [1]:
F-61AF6

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.